Introduction: In refractory status epilepticus (SE), because of subcellular maladaptive changes, GABAergic drugs are no longer effective, and the excitatory neurotransmitter glutamate (Glu) plays a major role in seizure perpetuation. Perampanel (PER, licensed since 09/2012) is the first orally active noncompetitive AMPA receptor antagonist for adjunctive treatment of refractory focal epilepsy. Methods: We analyzed treatment response, seizure outcome, and adverse effects of add-on treatment with perampanel in patients with refractory status epilepticus in the Neurological Intensive Care Unit (NICU), Salzburg, Austria between 09/2012 and 11/2014 by retrospective chart review. Results: Twelve patients (75% women) with refractory status epilepticus were treated with PER administered per nasogastric tube between 09/2012 and 11/2014. Median age was 75 years [range: 60-91]. The most frequent SE type was nonconvulsive SE (NCSE) with (5/12, 42%) and without coma (6/12, 50%). In seven patients (58%), SE arose de novo, with an acute symptomatic cause in five patients (42%). Cerebrovascular diseases (4/12, 33%) and cerebral tumors (4/12, 33%) were the most common etiologies. Perampanel was given after a median number of four antiepileptic drugs [range: 2-7] and a median time of 1.5 days [range: 0.8-18.3]. In one patient (8%), clinical improvement was observed within 24 h and EEG improvement within 60 h after administration of PER, while in another patient (8%), clinical and EEG improvement was observed more than 48 h after administration. Median initial dose was 4 mg [range: 2-12; SD: 4.11], titrated up to a median of 12 mg [range: 4-12] in steps of 2 to 4 mg per day. No adverse effects were reported regarding cardiorespiratory changes or laboratory parameters. Outcomes after SE were moderate disability in five patients (42%), death in three patients (25%), and persistent vegetative state in two patients (17%). Conclusion: Though glutamate plays a major role in seizure perpetuation, the noncompetitive AMPA receptor antagonist PER could only ameliorate seizure activity in a few patients with refractory SE. The long duration of SE before the administration of PER via nasogastric tube, as well as relatively low doses of PER, might be responsible for the modest result. Perampanel was well tolerated, and no adverse events were reported.
Introduction
Status epilepticus (SE) is a prolonged, self-sustaining seizure associated with high morbidity [1] and mortality rates up to 20% [2, 3] .
According to a new definition, status epilepticus is the failure of the mechanisms responsible for seizure termination or the initiation of mechanisms, which leads to abnormally prolonged seizures (t1) that might have long-term consequences (t2), including neuronal death, neuronal injury, and alteration of neuronal networks, depending on the type and duration of seizures [4] . An imbalance of the inhibitory activity of the neurotransmitter γ-amino butyric acid (GABA) and the excitatory neurotransmitter glutamate is suspected as the underlying pathophysiology of seizure perpetuation in status epilepticus [5, 6] . Fast and aggressive treatment of SE is important as survival rates decrease with seizure duration [7] . Treatment follows a staged approach with intravenous benzodiazepines, followed by intravenous AEDs. If seizure activity is ongoing, despite these interventions, SE is considered refractory, with urgent need of intensive care treatment and intravenous anesthetics [8, 9] . At this stage, subcellular maladaptive changes with internalization of postsynaptic GABA A receptors to the cytoplasm and changes in chloride homeostasis [5, 6, 10] make GABAergic drugs less efficacious or eventually ineffective. The excitatory neurotransmitter glutamate plays a major role in seizure perpetuation via alphaamino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptors at this stage.
Perampanel (PER) is the first orally active, noncompetitive AMPA receptor antagonist and was licensed by the EMA in 09/2012 for the adjunctive treatment of focal onset epilepsy in patients ≥12 years old. In a lithium-pilocarpine rat model of SE, the efficacy of diazepam and PER in refractory SE was assessed [11] . In this study, PER terminated seizure activity when administered 10 min (ED 50 : 1.7 mg/kg) and 30 min (ED 50 : 5.1 mg/kg) after SE onset, whereas diazepam 30 mg/kg did not terminate seizure activity at 30 min. Perampanel 8 mg/kg terminated seizure activity in all rats whether administered at 10 or 30 min, though strong CNS depressant effects (immobility, loss of righting reflex) were observed. Hence, efficacy of PER in the termination of benzodiazepineresistant SE was suggested, consistent with previous studies with other antiglutamatergic drugs in animal models [12] [13] [14] . Furthermore, a synergistic effect of coadministered low-dose diazepam (5 mg/kg) and PER (1 mg/kg) 30 min after SE onset resulted in seizure termination in all rats with only slight CNS depressant effects [15] .
Data on the efficacy of perampanel in the treatment of refractory SE in humans are missing. So far, there is only one case report on possible termination of focal SE (PER added as the last AED within 24 h of SE termination) in an 81-year-old patient [15] .
The aim of our study was to evaluate efficacy and safety of treatment with PER in patients with refractory and super-refractory SE in a neurological intensive care unit (NICU).
Material and methods
All patients who received perampanel (PER) as an add-on treatment in refractory and super-refractory SE at the Neurological Intensive Care Unit (NICU), Salzburg, Austria between 09/2012 and 11/2014 were analyzed. By retrospective chart review, we collected data on underlying SE etiology, SE type, SE duration, duration of stay in the NICU and in the hospital, number and sequence of administered AEDs before PER, response to PER treatment within 24, 48, and 72 h, outcome after SE, and adverse effects of the add-on treatment with perampanel.
The diagnosis of SE was made either clinically, in the case of SE with prominent motor symptoms, or using electroclinical criteria for NCSE proposed by Kaplan and Sutter [16] and Beniczky et al. [17] .
We used a clinical classification of SE types according to seizure semiology based on the proposal of the ILAE Task Force along with two taxonomic criteria: presence of motor symptoms and impairment of consciousness [4] . Hence, we distinguished between the following: (a) SE with prominent motor symptoms (including tonic-clonic SE, myoclonic SE, focal motoric SE, tonic SE and hyperkinetic SE) and (b) SE without prominent motor symptoms (NCSE) with or without coma.
With regard to etiology, we distinguished between symptomatic (or known cause) -which was further classified as acute symptomatic, remote symptomatic, and progressive symptomatic -and cryptogenic (or unknown cause) [18] .
Status epilepticus severity score (STESS, cutoff level for bad outcome: 3 points) [19] and Epidemiology-based mortality score in SE (EMSE, cutoff level for bad outcome: 64 points) [20] were used to estimate mortality risk.
Treatment followed a staged approach with stage one (intravenous benzodiazepines) and stage two (intravenous AEDs such as levetiracetam (LEV), phenytoin (PHT), valproic acid (VPA), or lacosamide Rhythmic Sharp Wave activity < 2.5 Hz right temporal Irregular Theta/Delta activity right temoral with intermittent SW 
Abbreviations: GPDs -generalized periodic discharges, LPDs -lateralized periodic discharges.
(LCM)) treatments. In case of ongoing seizure activity (clinically or ascertained by persistent EEG pattern) despite stage one and two treatments, SE was defined as refractory, and stage 3 treatment with propofol (PRO), midazolam (MDZ), or thiopental (THIO) was administered. Super-refractory SE was defined as persistent seizure activity for more than 24 h despite intravenous anesthetics. At this stage, other treatment options like intravenous ketamine (KET), magnesium (Mg), intravenous immunoglobulin (IVIG), and other new AEDs were given, according to the judgment of the ammending physician. Treatment response after the administration of PER was assessed based on clinical and EEG changes within 24 h and, because of the long half-life of perampanel (105 h), between 24 and 72 h, if no further therapy was added throughout that period of time. If another treatment was given within that time period, only those clinical and EEG changes prior to the succeeding drug were considered a response to PER.
Outcome after cessation of SE (defined as termination of clinical symptoms or cessation of seizure activity in the EEG) was assessed according to the Glasgow Outcome Scale (GOS) as follows: good recovery, moderate disability, severe disability, persistent vegetative state, and death. Death was rated if it occurred within 8 weeks of status epilepticus.
Blood samples including hemogram, C-reactive protein, basic metabolic panel including electrolytes, blood urea nitrogen, creatinine, glucose, liver enzymes, and levels of concomitant AEDs were taken regularly. All patients were under continuous cardiorespiratory monitoring at our NICU.
Statistics
Descriptive statistical analysis including calculation of frequencies as well as calculation of median [range], mean, and standard deviation was performed using Microsoft Excel. Because of the small sample size, no statistical comparison between responders and nonresponders as well as between survivors and nonsurvivors was performed.
Standard protocol approvals, registrations, and patient consents
This is a retrospective noninvasive study, which does not require ethics committee approval according to the Austrian Law on Research.
Results
Twelve patients (75% women) with refractory status epilepticus were treated with PER administered per nasogastric tube in the NICU between 09/2012 and 11/2014. Median age was 75 years [range: 60-91; SD: 10.8]. The most frequent SE type was nonconvulsive SE (NCSE) with (5/12, 42%) and without coma (6/12, 50%). In seven patients (58%), SE arose de novo, with an acute symptomatic cause in five patients (42%). Cerebrovascular diseases (4/12, 33%) and cerebral tumors (4/12, 33%) were the most common etiologies. In one patient with preexisting epilepsy, subtherapeutic plasma levels of the prescribed AEDs were assigned as cause of SE. For further details on patients' demographics, see Table 1 . Status epilepticus lasted less than 24 h in 7 patients (58%), which is defined as refractory SE, while that of the other 5 patients were classified as super-refractory SE with SE duration of one to seven days in three patients (25%) and more than 7 days in two patients (17%). Perampanel was given after a median number of four AEDs [range: 2-7] (for detailed therapeutic approach, see In two patients (17%), clinical improvement (improvement of vigilance, adequate responses, absence of subtle clinical ictal signs) was observed within 24 h after the administration of PER, wherein one patient had a relapse within another 24 h and was, therefore, considered a nonresponder. Clinical response in the other patient was observed more than 6 h after the administration of PER at a maximum dose of 12 mg, given 26 h after SE onset. Electroencephalographic improvement in this patient followed clinical improvement and was observed 60 h after the first administration of PER. The initial EEG of this patient showed right temporal rhythmic epileptiform discharges b2.5 Hz (Fig. 1 ) and periodic lateralized epileptiform discharges (PLEDs) with spatiotemporal evolution. Sixty hours after treatment initiation with PER, the EEG patterns changed and evolved into irregular theta/delta activity with intermittent sharp waves and spikes in the same location. In one further patient, clinical improvement was observed 72 h after the administration of PER without other escalation of therapy in between at a maximum dose of 12 mg of PER administered 28 h after SE onset. The initial EEG in this patient showed PLEDs (left temporal maximum) with fluctuation but no spatiotemporal evolution, which stopped 48 h after PER administration before clinical improvement (Fig. 2) . Outcomes after SE were moderate disability in five patients (42%), persistent vegetative state in two patients (17%), and death in three patients (25%). The patient with early treatment response had a comparatively good outcome with moderate disability, and with severe disability to the one with late treatment response. In the group of nonsurvivors, STESS score was true positive in two out of three patients (66%), and EMSE in all three patients (100%). Altogether, STESS and EMSE scores were positive in 8 out of 12 patients (75%) (STESS: PPV 25%, NPV 75%; EMSE: PPV 37.5%, NPV 100%) (see Tables 2-4 No adverse effects were reported regarding cardiorespiratory changes or laboratory parameters related to the administration of PER in all patients. Four patients (33%) were catecholamine-dependent on admission without documented increase of required doses after administration of PER. Plasma levels of concomitant AEDs were taken at a regular basis, without changes in plasma concentration after starting therapy with PER.
Discussion
Although glutamate plays a major role in seizure perpetuation in refractory and super-refractory status epilepticus, and efficacy of the noncompetitive AMPA receptor antagonist PER was observed in lithium-pilocarpine rat models with benzodiazepine-resistant SE [11] , we only observed moderate response in our sample of patients with refractory and super-refractory SE in the NICU. The median initial dose in our patients was 4 mg, titrated up to a maximum dose of 12 mg given after a median time of 1.5 days. The dose might be low compared to the preclinical SE models. In rats, the effective dose at which SE was terminated in 50% of the rats (ED 50 ) 30 min after SE onset was 5.1 mg/kg [11] . Furthermore, PER was administered intravenously in rats, whereas in humans, there is only an oral formulation available, which we administered via nasogastric tube. Perampanel administered orally is absorbed in the upper gastrointestinal tract with a median time to reach maximum concentration concentration (Tmax) of 1 h (range: 0.5-10.0) under fasting conditions in healthy subjects and a bioavailability of 100% when swallowed whole [21] . Bioavailability of perampanel administered crushed via nasogastric tube has not been investigated, yet solubility of PER is highest in acid conditions. Though not formally tested, single case reports [22, 23] suggest sufficient bioavailability of PER when administered via an enteral feeding tube. In critically ill patients, gastrointestinal absorption is diminished because of slow gastric emptying [24] , reduced intestinal expression of glucose transporters [25] , as well as other suspected mechanisms like reduced intestinal blood flow and mucosal factors [24] . Hence, the oral administration of PER, as well as its relatively low doses compared to the effective doses in rats, might be one explanation for the comparatively poor treatment response. Furthermore, PER has an apparent terminal half-life of~105 h, whereas the calculated effective half-life is 48 h, reaching a steady state after 10 to 19 days [21] ; therefore, assessment of treatment response within 24 h might be too early. A comedication with enzyme-inducing antiepileptic drugs, especially PHT in case of SE, might influence PER plasma levels and, therefore, efficacy of PER as well. Plasma levels of PER could not be determined in our hospital; therefore, we could not quantify this effect.
In addition, PER was given after a median time of 1.5 days, which might have been too late in the course of SE. The subcellular changes that lead to self-sustaining seizure activity are only partly discovered [5, 6] ; they are not fully understood yet at such an advanced stage of SE. An excessive seizure perpetuation, as seen in super-refractory SE, might reflect the severe underlying dysfunction of the brain. These factors might contribute to the modest success of PER, when given at the late stages of SE. In addition, our patient group was severely ill with many factors contributing to a poor prognosis: (i) in 42% of our patients, an acute symptomatic cause of SE was identified, reflecting an acute and severe brain damage with a poorer prognosis; and (ii) the median age of our patients was 74.6 years, and STESS and EMSE scores were high, suggesting a poor prognosis with a high negative predictive value of the EMSE score of 100%.
Conclusions
Though glutamate plays a major role in seizure perpetuation of SE, the noncompetitive AMPA receptor antagonist PER could only ameliorate seizure activity in a few patients with refractory and superrefractory SE. The relatively low doses (compared to the effective doses in animal models) of oral administration, the long duration of SE before the administration of PER, and the severe underlying brain dysfunction in patients with super-refractory SE might be responsible for the modest results. Regarding safety issues, no adverse effects could be observed both in cardiorespiratory and with respect to laboratory results including kidney function and liver enzymes. Hence, controlled testing for tolerability and safety of higher doses of PER in the treatment of SE as well as the earlier use of PER in refractory SE is warranted and a parenteral formula might increase treatment response and improve outcome.
